GURUGRAM, India - TelAve -- AliveCor, the global leader in AI-powered cardiology, today announced the launch of its revolutionary Kardia 12L ECG system in India, following its successful introduction in the United States. This is the world's first AI-powered, handheld 12-lead electrocardiogram (ECG) system with a unique single-cable design that can detect life-threatening cardiac conditions, including heart attack, with a reduced leadset.

Kardia 12L ECG, which has received Central Drugs Standard Control Organisation (CDSCO) approval for use in India, detects 35 cardiac determinations (14 arrhythmias and 21 morphologies) - including serious conditions like acute myocardial infarction (MI) and the most common types of cardiac ischemia - expanding critical access to accurate heart data within a broad range of healthcare settings.

"Kardia 12L enables physicians to rapidly detect diseases anytime, anywhere, making this critical medical device  more accessible than ever before," said Priya Abani, CEO of AliveCor. "More importantly, the launch of the Kardia 12L ECG system in India marks a big win for physicians and patients in the country, at a time when the healthcare system has never been more constrained, or more in need of the access and efficiency this type of solution provides."

More on TelAve News

• Voices Across the Men's Health Network:
• Bent Danholm To Be Featured On Global Podcast Network In Live Interview
• AdvoCast Expands Leadership in Strategic Comms with New Role Producing "Communication Breakdown" Podcast
• Rocket.Chat assessed "Awardable" for Department of Defense work in the CDAO's Tradewinds Solutions Marketplace
• Success for Global Communications Leader IQSTEL, Inc. Growing From $13 Million Revenue in 2018 to Nearly $300 Million Last Year

Cardiovascular disease (CVD) represents a significant and growing health challenge in India, making early and accurate diagnosis more critical than ever.

Conventional 12-lead ECG machines are the standard of care for detecting and diagnosing many heart conditions, but their availability can be limited due to their size and complexity. Using advanced KAI 12L and a reduced leadset, Kardia 12L offers outstanding clinical efficiency and performance substantially equivalent to state-of-the-art ECG analysis solutions. Its speed and simplicity assists healthcare providers in rapid disease detection and enhancing patient experience.

Kardia 12L is battery-operated, weighs just 135 grams and can fit in a physician's lab coat pocket, making it significantly smaller, more portable and more convenient than conventional 12-lead ECG machines. Its streamlined leadset also makes it less invasive for patients, who do not need to fully disrobe during a reading. The device requires minimal self-guided training and is simpler to use than standard 12-lead ECG machines.

For healthcare providers interested in purchasing Kardia 12L, please visit the AliveCor India Kardia12L website.

More on TelAve News

• Artbound: "The Cheech" Awarded Two 2025 LA Area EMMY Awards — Honored in ARTS & MUSIC COMPOSITION
• Rising Conservative Star Jordan Brace Emerges as Influential Political Voice with Elite Washington Connections
• Conservative Latinos for PA Shaping the Future of Hispanic Community, Guest State Treasurer Stacy Garrity
• Chasing Creative Plants Roots in Palm Coast, Builds Marketing Systems for Modern B2B Brands
• David M. White, DDS Celebrates 500 Five-Star Reviews in Reno

About AliveCor

AliveCor, Inc., the leading provider of FDA-cleared personal electrocardiogram (ECG) technology, is transforming cardiology with its medical-grade AI solutions. AliveCor is committed to providing innovative devices and services that empower patients and physicians with personalized and actionable heart data. With over 300 million ECGs recorded, the company's Kardia devices are the most clinically validated personal ECGs in the world and can remotely detect six of the most common heart arrhythmias in just 30 seconds. The company's latest offering, Kardia 12L ECG System, powered by KAI 12L to detect 35 cardiac conditions (14 arrhythmias and 21 morphologies), was designed exclusively for use by healthcare providers. AliveCor's enterprise platform allows third-party providers to manage their patients' and customers' heart conditions simply using state-of-the-art tools that provide easy front-end and back-end integration to AliveCor technologies, addressing gaps in care and improving the treatment experience for patients across a range of disease areas. AliveCor is a privately held company headquartered in Mountain View, California, USA.